IPP Bureau
Sigachi Industries FY25 revenue surges 25%, EBITDA 46%
By IPP Bureau - June 02, 2025
Newly commissioned MCC in Jhagadia and Dahej and CCS project expansions will unlock an additional 8,800 MTPA, fuelling year-over-year revenue gains of 20%-30% in excipients
Arvinas and Pfizer's Vepdegestrant significantly improves progression-free survival for patients with ESR1-Mutant, ER+/HER2- advanced breast cancer
By IPP Bureau - June 02, 2025
Vepdegestrant is the first and only PROteolysis TArgeting Chimera (PROTAC) evaluated in a Phase 3 clinical trial and the first to show benefit in patients with breast cancer
Keytruda plus Trodelvy reduced risk of disease progression by 35% V/s Keytruda plus cchemothrapy in first-line PD-L1+ TNBC
By IPP Bureau - June 02, 2025
First pivotal Phase 3 trial to show superiority of Keytruda plus a TROP2 antibody-drug conjugate, Trodelvy, versus standard of care in first-line metastatic TNBC
ICN to organize virtual discussion on "Digital Transformation: The Catalyst for Agile and Smarter Process" on June 4
By IPP Bureau - June 02, 2025
Speakers for the session are: Dr. Richard Lobo, Global Head Business Excellence, Innovation, R&D and Chief Ethics Counsellor, Tata Chemicals; Dr. Debabrata Rautaray, Vice President and Chief Product Development & Innovation Officer, DCM Shriram Chemicals Innovation Centre; Dr. Prashant Puri, Head - R&D, Deepak Fertilizers and Petrochemicals Corporation (DFPCL); Dr. Deepak S Panmand, General Manager (R&D), Dhanuka Agritech; Dr. Mudassir. K. Munshi, Team Leader, Deepak Nitrite; and Dr. Manish M. Khandagale, Senior Field Application Specialist, Revvity Signals
Revvity introduces new IVD reference standards for monitoring oncology diagnostic testing workflows
By IPP Bureau - June 02, 2025
Revvity launches its first set of IVD Mimix reference standards, providing diagnostic labs with trusted quality controls for optimizing tests and monitoring workflows
Sanofi acquires US biopharma firm Blueprint Medicines for $9.1 billion
By IPP Bureau - June 02, 2025
Adds fast-growing and only approved medicine for advanced and indolent systemic mastocytosis to the Sanofi portfolio
QMS Medical Allied Services posts 134.36% jump in consolidated PAT in Q4 FY25
By IPP Bureau - May 31, 2025
Operating income on consolidated basis increased by 38.10% at Rs 44.58 crore in Q4 FY25
Paras Health Gurugram raises alarm over surge in tobacco-related cancers
By IPP Bureau - May 31, 2025
Approximately 35% of male cancer patients and 12% of female cancer patients at Paras Health were diagnosed with tobacco-related cancers
Pfizer’s Braftovi combination regime reduces death risk for patients with BRAF V600E mutant mCRC
By IPP Bureau - May 31, 2025
Pivotal results from the Phase 3 Breakwater trial showed 51% risk reduction in death compared to standard-of-care treatment
Merck’s MK-1084 shows antitumor activity in Phase 1 trial of patients with advanced colorectal cancer
By IPP Bureau - May 31, 2025
Manageable safety profile and encouraging antitumor activity observed for MK-1084 in KANDLELIT-001, both as a monotherapy and in studied combinations
Procter & Gamble Hygiene and Health Care posts Q3 FY25 PAT at Rs. 156 Cr
By IPP Bureau - May 30, 2025
The company also announced results for the third quarter, reporting sales at Rs. 992 crore, flat versus year ago
Alkem reports 7.1% YoY revenue growth in Q4 FY25
By IPP Bureau - May 30, 2025
Annual EBITDA margin expands by 170 basis points
Sudeep Pharma acquires Nutrition Supplies Services
By IPP Bureau - May 30, 2025
This strategic move positions Sudeep Pharma to seamlessly integrate high-end premix capabilities with its mineral portfolio
